U.S., April 14 -- ClinicalTrials.gov registry received information related to the study (NCT07526194) titled 'A Study in Healthy Men to Test How Well Different Doses of BI 3821001 Are Tolerated' on March 31.
Brief Summary: The main objectives of this trial are to investigate safety, tolerability and pharmacokinetics (PK) of BI 3821001 in healthy male trial participants.
Study Start Date: April 22
Study Type: INTERVENTIONAL
Condition:
Healthy
Intervention:
DRUG: BI 3821001
BI 3821001
DRUG: Placebo
Placebo
Recruitment Status: NOT_YET_RECRUITING
Sponsor: Boehringer Ingelheim
Disclaimer: Curated by HT Syndication....